UBS stuft ASTRAZENECA auf Sell ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Astrazeneca auf "Sell" mit einem Kursziel von 9900…
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower…
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of…
Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value…
Biotech Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover The company is working on radiopharmaceuticals treatments for cancer.…
AstraZeneca: Der Pharma-Riese bleibt in Sachen M&A sehr aktiv - Aktienanalyse Kulmbach (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie des…
AstraZeneca is paying $2.4bn for Fusion Pharmaceuticals - but actually is it getting AstraZeneca PLC (LSE:AZN) is acquiring Canadas Fusion Pharmaceuticals for $2.4 billion, in a bid to effectively keep up with Joneses…
AstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchase The deal is AstraZenecas second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to…